Vanguard Group Inc. increased its position in shares of Aimmune Therapeutics, Inc. (NASDAQ:AIMT) by 30.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 2,199,858 shares of the biotechnology company’s stock after buying an additional 513,803 shares during the period. Vanguard Group Inc.’s holdings in Aimmune Therapeutics were worth $47,803,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Alliancebernstein L.P. increased its position in Aimmune Therapeutics by 4.9% in the first quarter. Alliancebernstein L.P. now owns 750,640 shares of the biotechnology company’s stock worth $16,311,000 after buying an additional 34,913 shares during the last quarter. American International Group Inc. increased its position in Aimmune Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 16,184 shares of the biotechnology company’s stock worth $352,000 after buying an additional 1,070 shares during the last quarter. Victory Capital Management Inc. acquired a new position in Aimmune Therapeutics during the first quarter worth about $1,064,000. Swiss National Bank increased its position in Aimmune Therapeutics by 17.5% in the first quarter. Swiss National Bank now owns 36,974 shares of the biotechnology company’s stock worth $803,000 after buying an additional 5,500 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in Aimmune Therapeutics by 454.1% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,979 shares of the biotechnology company’s stock worth $130,000 after buying an additional 4,900 shares during the last quarter. 69.51% of the stock is currently owned by hedge funds and other institutional investors.

Aimmune Therapeutics, Inc. (AIMT) traded up 0.26% during trading on Friday, hitting $19.03. 23,450 shares of the company were exchanged. The firm’s 50 day moving average price is $20.99 and its 200-day moving average price is $19.94. The stock’s market capitalization is $961.68 million. Aimmune Therapeutics, Inc. has a 1-year low of $12.38 and a 1-year high of $27.31.

Aimmune Therapeutics (NASDAQ:AIMT) last issued its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.65) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.64) by $0.01. Equities analysts predict that Aimmune Therapeutics, Inc. will post ($2.68) EPS for the current year.

WARNING: “Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Position Boosted by Vanguard Group Inc.” was first reported by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another website, it was copied illegally and reposted in violation of international copyright legislation. The original version of this article can be read at https://www.watchlistnews.com/aimmune-therapeutics-inc-nasdaqaimt-position-boosted-by-vanguard-group-inc/1475107.html.

A number of equities analysts recently issued reports on the stock. Wedbush reissued an “outperform” rating and issued a $42.00 price objective on shares of Aimmune Therapeutics in a report on Monday, July 24th. Piper Jaffray Companies set a $38.00 price objective on shares of Aimmune Therapeutics and gave the stock a “buy” rating in a report on Thursday, July 27th. Zacks Investment Research downgraded shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, July 27th. Finally, ValuEngine raised shares of Aimmune Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, June 13th. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $33.00.

In related news, insider Susan E. Barrowcliffe sold 15,000 shares of the stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $20.26, for a total value of $303,900.00. Following the transaction, the insider now owns 15,000 shares in the company, valued at approximately $303,900. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Stephen George Dilly sold 49,400 shares of the stock in a transaction that occurred on Friday, June 23rd. The stock was sold at an average price of $20.21, for a total transaction of $998,374.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 188,470 shares of company stock worth $3,942,092. 24.56% of the stock is owned by corporate insiders.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Want to see what other hedge funds are holding AIMT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aimmune Therapeutics, Inc. (NASDAQ:AIMT).

Institutional Ownership by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.